Compare PAX & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | KLRA |
|---|---|---|
| Founded | 1988 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2020 | 2026 |
| Metric | PAX | KLRA |
|---|---|---|
| Price | $9.54 | $12.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $14.83 | ★ $42.75 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.22 | N/A |
| Revenue Next Year | $9.41 | N/A |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.03 | $9.76 |
| 52 Week High | $17.80 | $23.82 |
| Indicator | PAX | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 51.95 |
| Support Level | N/A | $9.76 |
| Resistance Level | $11.74 | $19.15 |
| Average True Range (ATR) | 0.40 | 0.79 |
| MACD | -0.21 | 0.13 |
| Stochastic Oscillator | 23.40 | 61.42 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.